Open AccessSplice variants of androgen receptor and prostate cancer
Author(s) -
Orazio Caffo,
Francesca Maines,
Antonello Veccia,
Stefania Kinspergher,
Enzo Galligioni
Publication year - 2016
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2016.297
Subject(s) - prostate cancer , medicine , androgen receptor , splice , androgen , cancer , prostate , cancer research , hormone , hormonal therapy , enzalutamide , oncology , bioinformatics , biology , gene , genetics
Over the last ten years, two new-generation hormonal drugs and two chemotherapeutic agents have been approved for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop secondary resistance. It has recently been suggested that the presence of androgen receptor splice variants plays a leading role in the primary and secondary resistance to the new hormonal drugs, whereas their presence seem to have only a partial effect on the activity of the chemotherapeutic agents. The aim of this paper is to review the published data concerning the role of androgen receptor splice variants in prostate cancer biology, and their potential use as biomarkers when making therapeutic decisions